![]() Valerie Odegard, Ph.D., has been named president and chief scientific officer, and Naomi Hunder, M.D., has been named chief medical officer. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals. (Nasdaq: SBTX) ('Silverback') today announced that the U.S. The company also announced two key executive promotions. SEATTLE, October 21, 2022-Silverback Therapeutics, Inc. SBT6050 is currently in a Phase 1 clinical study in patients with advanced or metastatic HER2-expressing solid tumors ( Identifier: NCT04460456). Silverback’s lead product candidate, SBT6050, is a therapeutic comprised of a TLR8 agonist payload conjugated to a HER2-directed monoclonal antibody that targets tumors such as certain breast, gastric and non-small cell lung cancers. ![]() Initially, the company is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Its platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Silverback Therapeutics is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC TM technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases. The company intends to use the proceeds to support its clinical development of SBT6050, a TLR8 agonist conjugated to a HER2-directed antibody currently in a Phase 1 clinical study for the treatment of HER2-expressing solid tumors, and to advance its pipeline of other ImmunoTAC therapeutics. Silverback Therapeutics will lay off 27 of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report. Venture Partners, Nextech Invest Ltd., Hunt Technology Ventures, and Pontifax Venture Capital. The round was led by EcoR1 Capital with participation from new investors including Boxer Capital of Tavistock Group, Fidelity Management & Research Company LLC, Nantahala Capital Management, and RA Capital and existing investors OrbiMed Advisors, U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |